Literature DB >> 19561475

Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation.

Thomas Schnelldorfer1, Vicente E Torres, Shaheen Zakaria, Charles B Rosen, David M Nagorney.   

Abstract

OBJECTIVE: To identify operative morbidity, mortality, and long-term outcome after operative treatment for symptomatic polycystic liver disease (PLD) and develop a treatment algorithm for patients with PLD.
BACKGROUND: PLD represents a challenging clinical problem that can result in massive hepatomegaly and various complications, leading to significant decline in health status and quality of life. The optimal surgical treatment for this disease is still evolving.
METHODS: All patients who underwent hepatic resection, cyst fenestration, or liver transplantation for PLD from 1985 to 2006 were identified retrospectively. Long-term outcomes were evaluated by patient survey. Mean follow-up was 8 +/- 0.5 years.
RESULTS: Of 141 patients (122 women; age: 51 +/- 1 years) with PLD, 117 had concomitant polycystic kidney disease. All patients suffered from symptomatic hepatomegaly with 85% being functionally impaired (Eastern Cooperative Oncology Group Performance Status: 1-3). Despite significant inferior vena cava or hepatic venous compression in 65%, hepatic function was commonly preserved. A total of 124 patients underwent partial hepatectomy with cyst fenestration, 10 underwent cyst fenestration alone, and 7 underwent liver transplantation for primary treatment of PLD. Overall operative morbidity and mortality was 58% and 4%, respectively, with major complications (Clavien grade: III-V) in 30%. Five- and 10-year survival was 90% and 78%, respectively. Eastern Cooperative Oncology Group Performance Status performance status normalized or improved in 75% of patients and 73% returned to work full-time. At follow-up, health survey scores were similar to the general population despite subsequent recurrence of symptoms in 73% of patients.
CONCLUSION: Selective patients with massive hepatomegaly from PLD benefit from operative intervention. The type of operation performed is mainly dependent on the distribution of the cysts, coincident sectoral vascular patency and parenchymal preservation, and hepatic reserve. Hepatic resection can be performed with acceptable morbidity and mortality, prompt and durable relief of symptoms, and maintenance of liver function. Cyst fenestration and liver transplantation, though effective in selected patients, are less broadly applicable.

Entities:  

Mesh:

Year:  2009        PMID: 19561475     DOI: 10.1097/SLA.0b013e3181ad83dc

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  42 in total

Review 1.  Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases.

Authors:  Bassam Abu-Wasel; Caolan Walsh; Valerie Keough; Michele Molinari
Journal:  World J Gastroenterol       Date:  2013-09-21       Impact factor: 5.742

2.  ERCP for the treatment of bile leak after partial hepatectomy and fenestration for symptomatic polycystic liver disease.

Authors:  Nayantara Coelho-Prabhu; David M Nagorney; Todd H Baron
Journal:  World J Gastroenterol       Date:  2012-07-28       Impact factor: 5.742

3.  Alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy: a pooled analysis.

Authors:  Tom J G Gevers; Frederik Nevens; Vicente E Torres; Marie C Hogan; Joost P H Drenth
Journal:  Liver Int       Date:  2015-11-09       Impact factor: 5.828

Review 4.  Evaluation and management of pain in autosomal dominant polycystic kidney disease.

Authors:  Marie C Hogan; Suzanne M Norby
Journal:  Adv Chronic Kidney Dis       Date:  2010-05       Impact factor: 3.620

5.  Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.

Authors:  Marie C Hogan; Tetyana V Masyuk; Linda J Page; Vickie J Kubly; Eric J Bergstralh; Xujian Li; Bohyun Kim; Bernard F King; James Glockner; David R Holmes; Sandro Rossetti; Peter C Harris; Nicholas F LaRusso; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2010-04-29       Impact factor: 10.121

6.  Mass effect from hepatomegaly in polycystic kidney disease.

Authors:  Anil Chalisey; Mahzuz Karim
Journal:  J Gen Intern Med       Date:  2014-08-16       Impact factor: 5.128

7.  Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Authors:  Arlene B Chapman; Olivier Devuyst; Kai-Uwe Eckardt; Ron T Gansevoort; Tess Harris; Shigeo Horie; Bertram L Kasiske; Dwight Odland; York Pei; Ronald D Perrone; Yves Pirson; Robert W Schrier; Roser Torra; Vicente E Torres; Terry Watnick; David C Wheeler
Journal:  Kidney Int       Date:  2015-03-18       Impact factor: 10.612

8.  Peri-operative challenges and long-term outcomes in liver transplantation for polycystic liver disease.

Authors:  Roberto Gedaly; Paige Guidry; Daniel Davenport; Michael Daily; Jens Ronsenau; Malay Shah; Michael A Cooper; Jonathan Hundley
Journal:  HPB (Oxford)       Date:  2012-09-21       Impact factor: 3.647

Review 9.  Renal transplantation in autosomal dominant polycystic kidney disease.

Authors:  Nada Kanaan; Olivier Devuyst; Yves Pirson
Journal:  Nat Rev Nephrol       Date:  2014-06-17       Impact factor: 28.314

10.  Development and Validation of a Disease-Specific Questionnaire to Assess Patient-Reported Symptoms in Polycystic Liver Disease.

Authors:  Myrte K Neijenhuis; Tom J G Gevers; Marie C Hogan; Patrick S Kamath; Titus F M Wijnands; Ralf C P M van den Ouweland; Marie E Edwards; Jeff A Sloan; Wietske Kievit; Joost P H Drenth
Journal:  Hepatology       Date:  2016-04-15       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.